Research and Development

SSI is one of Denmark’s largest research institutions in the health sector.
More about SSI's research and development

R and DSSI is one of Denmark’s largest research institutions in the health sector
Contract ServicesSSI provides contract work within our core activities and competences
Job and CareerRead about SSI as a workplace and meet some of our employees
EPI-NEWSNational surveillance of communicable diseases
Girl in the rain

New mission and strategy

SSI has produced a new strategy with a focus on infectious disease preparedness, biobanking and biomarkers, and research. Read more about SSI's new strategy...
Danish National Biobank

The Danish National Biobank

The Danish National Biobank gives scientists from Denmark and abroad overview and access to more than 16 million biological samples in both existing and future collections. Read more about the Danish National Biobank...
The season was very prolonged and characterised by a high number of influenza cases, among which influenza B was dominant.
For the third time, SSI will host the annual European pertussis meeting, EUPertstrain/EUPertgenomics.
In 2017, the coverage of all vaccines in the childhood vaccination programme rose. For several vaccines, the increase was quite...

More news...

Vaccination recommendations for foreign travel
Pilgrimages to Mecca
Conclusion of vaccination series with Cervarix® in the ch...
Imported malaria 2017
Botulism outbreak in Southern Jutland
MRSA 2017
The 2017/2018 influenza season
Syphilis 2017

More EPI-NEWS...

Statens Serum Institut (SSI) in Copenhagen Denmark has been granted a sum of EUR 13.8 million from the European & Developing Countries Cl...
Scientists at SSI have developed a new potential vaccine against infections from the enteropathogen, Clostridium difficile (CD).
The number of tuberculosis cases among Swedish and Finnish indigenous citizens falls faster than in Denmark shows a new Nordic survey.
New research from CVIVA shows that Danish children, who have received the live MMR vaccine together with the non-live DTaP-IPV-Hib vaccin...

More R and D News...

Available Positions:

Currently, we have no available positions.